Intellia Therapeutics, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- John M. Leonard
- Full Time Employees
- 377
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 40 Erie Street Cambridge MA United States 02139
- IPO Date
- May 6, 2016
- CIK
- 0001652130
- Website
- intelliatx.com
- Similar Companies
- Business
- Intellia Therapeutics, Inc. Intellia Therapeutics, Inc. (NTLA) is a clinical-stage biotechnology company focused on developing potentially curative CRISPR/Cas9-based gene editing therapeutics for severe genetic diseases, cancers, and autoimmune disorders; its core pipeline includes nexiguran ziclumeran (nex-z, formerly NTLA-2001) in Phase 3 trials for transthyretin (ATTR) amyloidosis with polyneuropathy (ATTRv-PN) and cardiomyopathy (ATTR-CM), lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) in Phase 3 HAELO trial for hereditary angioedema (HAE) with topline data expected mid-2026, NTLA-3001 for ATTR amyloidosis, NTLA-4001 for T-cell malignancies, and research programs in hemophilia B (partnered with Regeneron Pharmaceuticals, Inc.), hematological disorders such as sickle cell disease and beta-thalassemia, as well as immuno-oncology and autoimmune disease targets. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company leverages a modular gene editing platform for in vivo and ex vivo therapies, supported by collaborations including Regeneron for ATTR amyloidosis co-development and cost reimbursements. Recent developments encompass completion of enrollment in the Phase 3 HAELO trial for lonvo-z in September 2025 ahead of schedule, presentation of positive longer-term Phase 1/2 data for nex-z and lonvo-z at ACAAI 2025 and other conferences, advancement in the Phase 3 MAGNITUDE trial for ATTR-CM, a strategic reorganization in early 2025 to prioritize late-stage programs, inducement equity grants under the 2024 Inducement Plan to support expansion, and a cash position of approximately $670 million as of Q3 2025 expected to fund operations into mid-2027 including potential U.S. commercial launch of lonvo-z in H1 2027.
Company News
Intellia Therapeutics (NASDAQ:NTLA) and Neurogene (NASDAQ:NGNE) Critical Survey
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
Intellia Therapeutics Appoints Jing L. Marantz, M.D.
Contrasting United Therapeutics (NASDAQ:UTHR) & Intellia Therapeutics (NASDAQ:NTLA)
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?
Intellia Therapeutics (NASDAQ:NTLA) Stock Picked Up by Analysts at Barclays
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Financial Review: Intellia Therapeutics (NASDAQ:NTLA) vs. Bicycle Therapeutics (NASDAQ:BCYC)
Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?
Intellia Therapeutics (NASDAQ:NTLA) Stock Crosses Below Fifty Day Moving Average – What’s Next?
Intellia Therapeutics, Inc. (NTLA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
3 Promising Genomics Stocks in the Spotlight in 2026
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
Public Employees Retirement System of Ohio Invests $1.49 Million in Intellia Therapeutics, Inc. $NTLA
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
Bank of New York Mellon Corp Makes New $6.95 Million Investment in Intellia Therapeutics, Inc. $NTLA